Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted): 2022-2025
Historic EPS (Weighted Average and Diluted) for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$0.09.
- Taysha Gene Therapies' EPS (Weighted Average and Diluted) rose 10.00% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.33, marking a year-over-year decrease of 152.38%. This contributed to the annual value of -$0.36 for FY2024, which is 62.50% up from last year.
- Per Taysha Gene Therapies' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.09 for Q3 2025, which was down 0.00% from -$0.09 recorded in Q2 2025.
- Taysha Gene Therapies' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.92 during Q4 2023, with a 5-year trough of -$1.32 in Q1 2022.
- For the 3-year period, Taysha Gene Therapies' EPS (Weighted Average and Diluted) averaged around -$0.12, with its median value being -$0.09 (2025).
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 192.93% in 2023, then tumbled by 107.61% in 2024.
- Quarterly analysis of 4 years shows Taysha Gene Therapies' EPS (Weighted Average and Diluted) stood at -$0.99 in 2022, then soared by 192.93% to $0.92 in 2023, then slumped by 107.61% to -$0.07 in 2024, then rose by 10.00% to -$0.09 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.09 for Q3 2025, versus -$0.09 for Q2 2025 and -$0.08 for Q1 2025.